Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34-selected autologous peripheral blood stem cells (Fred Hutchinson Cancer Center)
- Development stage
- Unknown
- Lead developer
- Fred Hutchinson Cancer Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34-selected autologous peripheral blood stem cells is an investigational cell therapy developed by the Fred Hutchinson Cancer Center for the treatment of chronic lymphocytic leukemia (CLL). The procedure involves the collection of a patient's own peripheral blood stem cells (PBSCs) followed by an ex vivo selection process to enrich for CD34+ hematopoietic stem and progenitor cells. This selection serves to purge the graft of contaminating malignant CLL cells (B-lymphocytes), which are typically CD34-negative, thereby reducing the risk of re-infusing cancer cells. Following myeloablative conditioning with high-dose chemotherapy and total body irradiation, the purified stem cells are transplanted back into the patient to restore bone marrow function and hematopoiesis.
- Other names
- CD34-selected PBSCCD-34-selected PBSCCD 34-selected PBSCautologous CD34+ PBSC transplantCD34-selected peripheral blood stem cell transplantationCD-34-selected peripheral blood stem cell transplantationCD 34-selected peripheral blood stem cell transplantation
Beyond the preview
Go deeper on CD34-selected autologous peripheral blood stem cells (Fred Hutchinson Cancer Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34-selected autologous peripheral blood stem cells (Fred Hutchinson Cancer Center).